Faculty Collaboration Database

NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology. J Clin Apher 2016 Feb;31(1):38-47

Date

05/06/2015

Pubmed ID

25940408

DOI

10.1002/jca.21400

Scopus ID

2-s2.0-84954383791 (requires institutional sign-in at Scopus site)   6 Citations

Abstract

The National Heart Lung and Blood Institute (NHLBI) hosted a two-day state of the science symposium on therapeutic apheresis in Bethesda, MD on November 28th-29th, 2012. The purpose of the symposium was multifaceted, and included the following aims: (a) To discuss this state of research and key scientific questions in apheresis medicine; (b) To identify gaps in knowledge for relevant cardiovascular diseases, hematological and oncological diseases, infectious diseases and sepsis, renal diseases, and neurological diseases where there may be strong therapeutic rationale for the application of apheresis treatments; (c) To explore ways of coordinating therapeutic apheresis with other medical disciplines and treatment modalities; (d) To identify and prioritize the most important research questions to be answered in apheresis medicine; and (e) To offer NHLBI suggestions on how a structured research approach can be applied to the therapeutic apheresis research agenda in future years. The following document summarizes three such key proposals presented at the meeting for evaluating apheresis therapy for the treatment of pain in sickle cell disease, heparin induced thrombocytopenia, and leukostasis from acute myeloid leukemia. The challenges and limitations regarding apheresis therapy for each disease are discussed, and avenues for future investigation for each disease are outlined.

Author List

Karafin MS, Sachais BS, Connelly-Smith L, Field JJ, Linenberger ML, Padmanabhan A

Author

Joshua J. Field MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Anemia, Sickle Cell
Autoantibodies
Blood Component Removal
Hematology
Heparin
Humans
Leukemia, Myeloid, Acute
Medical Oncology
National Heart, Lung, and Blood Institute (U.S.)
Platelet Factor 4
United States